Cubist Announces Positive Phase 3 Trial Results for Ceftolozane/Tazobactam in Intra-Abdominal Infections
December 16, 2013 at 07:48 AM EST
Cubist Pharmaceuticals (NASDAQ: CBST ) today announced positive top-line results from the Company's pivotal Phase 3 clinical trial of its antibiotic candidate ceftolozane/tazobactam in complicated
